MB-SBPH@EC2704A

Xie Bing increases holdings of China Biopharmaceutical

China BIO-TECHNOLOGY ANNOUNCES 2025 ANNUAL GENERAL MEETING DATE AND AGENDA

China Biopharmaceuticals Repurchased 1.83 Million Shares for 10.0088 Million HKD on April 29, 2026

Zhang Xiangling Increased Holdings in China Biopharmaceuticals

China Biopharmaceuticals repurchases 1.81 million shares for over HK$10 million

China Bio Pharmaceutical repurchased 1.78 million shares for HKD 10.089 million

China Biopharm's Subsidiary Showcases LM-364 and LM-338 Preclinical Data, LM-364 Files FDA IND

China Biologic Pharmaceuticals Announces Latest Data on Two New ADCs

China Bio-Pharmaceuticals Repurchased 1.73 million Shares

Maxomics' Bomocutamab Combined with Anlotinib Approved for Marketing by NMPA

China Biopharmaceutical Obtains Approval for Drug Combination to Treat Alveolar Soft Part Sarcoma

China Biologic Discloses Latest Clinical Data on PD-1/VEGF Bispecific Antibody

China Biopharmaceutical Reports Initial Results of LM-299 Study

China BioPharmaceutical Begins Phase III Clinical Trial of LM-302

Morgan Stanley Raises Target Price for China Bio-Pharmaceuticals to HKD 8.3

Innovative Drug Developed by Subsidiary of China Biopharmaceutical Completes First US Patient Enrollment

China BioPharmaceutical's New Drug TQB3205 Receives FDA Research Application Approval

Xie Bing 增持中国生物制药股份至 9.02%

CMBI Downgrades China Bio-Pharmaceutical Target Price to HKD 7.7, Maintains Buy Rating

Xie Qirun Increased Holdings in China Bio-Pharmaceuticals by 1.748 Million Shares

SOMERLEY CAP

TIANLI HOLDINGS

CPM GROUP

FUTONG TECH

NICHE-TECH SEMI

SINO ICT

COSMOS MACH

UBOT HOLDING

SAMPLE TECH

PERENNIAL INT'L

01177

Sino Biopharmaceutical (HK:1177) has announced a hybrid annual general meeting scheduled for June 17, 2025, allowing both in-person and online participation. The agenda includes reviewing the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting authority to issue up to 20% of the company’s share capital. Analysts rate the stock as a Buy with a target price of HK$8.70. The company focuses on biopharmaceutical and chemical medicines in the healthcare sector, with a market cap of HK$99B.

Tip Ranks

SBP GROUP

Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate

560600

516930

512290

159849

159316

159929

Sino Biopharmaceutical's unit LaNova Medicines presented promising preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the AACR Annual Meeting 2026. These ADCs target solid tumors, with LM-364 showing strong antitumor activity and a favorable safety profile, progressing towards an IND filing with the U.S. FDA. LM-338 demonstrated high target specificity, indicating potential for future pipeline expansion. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy with a price target of HK$8.70, reflecting confidence in its oncology-focused innovations.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

China Universal 800 Health Care ETF

Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026

08037

512010

510660

Sino Biopharmaceutical's subsidiary LaNova Medicines presented promising early clinical data for MK-2010/LM-299, a PD-1/VEGF bispecific cancer drug licensed to Merck. In a Phase 1/2 study with 112 patients, the drug demonstrated a manageable safety profile and notable efficacy signals, particularly in non-small cell lung cancer, with an overall response rate of 55% at 20 mg/kg. This development enhances Sino Biopharmaceutical's position in oncology and underscores the strategic partnership with Merck. Analysts rate the stock as a Buy with a target price of HK$8.70.

CH BIOTECH SER

E Fund CSI 300 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Dacheng CSI All Share Health Care Equipment and Services ETF

Merck

Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck

06990

09926

06181

01801

00100

02513

03317

06869

01772

SKB BIO(06990) rose 6.97%, with a trading turnover 458.1 Million HKD, and a year-to-date rose 32.3%. AKESO(09926) rose 6.89%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 30.4%. MINIMAX-W(00100) fell 10.88%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 413.6%. KNOWLEDGE ATLAS(02513) fell 8.54%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 646.1%.

Top Gainers&Losers

SKB BIO

AKESO

LAOPU GOLD

INNOVENT BIO

MINIMAX-W

KNOWLEDGE ATLAS

XUNCE

YOFC

GANFENGLITHIUM

Top 5 HK Stock Gainers/Losers (>100B) (4.15)

Morgan Stanley published a research report, updating its risk-return assessment for SBP GROUP. The group's sales are expected to decline by 1%, 3%, and 3% respectively from 2026 to 2028. It is anticipated that the company's revenue will grow by 11% this year, benefiting from advance payments from Sanofi, as well as innovative drugs and biosimilars recording over 20% year-on-year growth, which is sufficient to offset the decline in the unit numbers of generic drugs. Morgan Stanley raised the group's target price from 8 yuan to 8.3 yuan, with a rating of "Overweight."

AASTOCKS

Morgan Stanley raises the target price of Zhongsheng Pharmaceutical to 8.3 yuan, rating it as "Overweight."

44080

Reuters

SIHUAN PHARM PREF OFFER

iShares Biotechnology ETF

SPDR S&P Health

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Navidea Biopharm

ALPS Medical Breakthrough

iShares Global Healthcare

VanEck Biotech ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VG Health

Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 "Pan-Kras Inhibitor" Approved By FDA

Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has received FDA approval for TQB3205, an oral pan-KRAS inhibitor targeting advanced malignant tumors. This drug aims to address a wider range of KRAS mutations, which are linked to about 30% of cancers globally. The company is expanding its oncology portfolio, complementing its existing G12C inhibitor, Garsorasib. Analysts rate Sino Biopharmaceutical (HK:1177) as a Buy with a price target of HK$8.70. The company focuses on innovative drug development in oncology and other therapeutic areas, with a market cap of HK$113.2B.

Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205

01347

06809

01072

01093

01171

00883

YOFC(06869) rose 18.94%, with a trading turnover 6.8 Billion HKD, and a year-to-date rose 334.8%. HUA HONG SEMI(01347) rose 14.68%, with a trading turnover 3.2 Billion HKD, and a year-to-date rose 22.5%. SBP GROUP(01177) fell 4.58%, with a trading turnover 848.3 Million HKD, and a year-to-date fell 2.3%. CSPC PHARMA(01093) fell 4.12%, with a trading turnover 857.3 Million HKD, and a year-to-date rose 10.4%.

MB-SBPH@EC2704A(28740.HK)